An OIS showcase featuring European ophthalmic start-ups was long overdue.
Not only will you see presentations from 8 innovative companies but a keynote discussion with Tim Clover,
CEO of Rayner and a panel discussion with some of the top European industry executives.
PROUDLY SPONSORED BY:
Allergan
Allergan (NYSE: AGN) is a unique, global pharmaceutical company focused on developing, manufacturing and commercializing high quality generic and innovative branded pharmaceutical products for patients around the world. The Company has approximately 30,000 employees worldwide and maintains global headquarters in Dublin, Ireland.
Oxurion
Oxurion (Euronext Brussels: OXUR) is a biopharmaceutical company developing treatments to preserve vision in patients with diseases affecting the back of the eye. The company has built a diverse portfolio of disease-modifying therapies, including treatments for diabetic eye disease, a leading cause of blindness in people of working age worldwide. Headquartered in Leuven, Belgium, Oxurion is listed on the Euronext Brussels exchange under the symbol OXUR. In the US, Oxurion NV operates ThromboGenics inc. as a subsidiary company.
MEDIA PARTNER:
AGENDA | SEPTEMBER 23
12:00 – 12:05 PM
Welcome and Introduction to OIS
Presented By:
Bill Link, PhD, Managing Partner - Flying L Partners
12:05 – 12:15 PM
European Ophthalmology Market Overview: Legacy of Innovation in Europe Past to Present Day
Presented By:
Joe Sullivan, CEO - Emmetropes
12:15 – 12:45 PM
Rayner: A European Innovation Success Story
Participant:
Tim Clover, CEO - Rayner
Interviewed By:
Joe Sullivan, CEO - Emmetropes
12:45 – 1:30 PM
European Company Showcase
Introduced By:
Mark Mayhew, Partner - Emmetropes
Oxurion | Patrik De Haes, MD, CEO
Voptica | Pablo Artal, PhD, Co-founder & CEO
Oculis | Marcia de Souza Lima, MD, Chief Medical Officer
Implandata Ophthalmic Products GmbH | Max G. Ostermeier, MBA, Founder & CEO
Resono Ophthalmic | Alfredo Ruggeri, President & CEO
KERANOVA | Michael Brownell, Strategic Advisor
1:30 – 2:30 PM
The Future of Ophthalmic Innovation in Europe - Drivers & Challenges
Participants:
Laurent Attias, SVP, Corporate Development Strategy, BD&L and M&A - Alcon
Jean-Frédéric Chibret, President - Théa
Fabrizio Chines, CEO - SIFI
Andrea Ponti, Managing Partner & Founder - GHO Capital
Dietrich Wolf, CEO – Eye Tech Care
Moderated By:
Javier Mendicute, MD, PhD
2:30 – 3:15 PM
Virtual Networking
GET INVOLVED
Learn how your company can get involved in another successful OIS meeting.